AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 171 min read$ORMP

ORAMED PHARMACEUTICALS INC. (ORMP): Submission of Matters to a Vote of Security Holders

ORAMED PHARMACEUTICALS INC. (ORMP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 15, 2026, the Company held its 2026 Annual Meeting of Stockholders. The final voting results at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) are set forth below. Proposal No. 1 - Re-ele

Original reporting
SEC EDGAR 8-K
Published Sep 17, 2026, 7:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 7:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$ORMP
Neutral
high confidence
Mentioned
$ORMP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ORMPNeutralLow
01

Why it matters

The filing confirms routine governance actions with no material operational or financial changes.

02

Market read

A standard corporate‑governance disclosure; limited relevance for traders.

03

What to watch

Potential future compensation alignment changes from the new say‑on‑pay frequency.

Relevance 6/10Novelty 3/10Timing: filed Sep 17, 2026, two days after the annual meeting

Background

ORMP held its 2026 Annual Meeting on Sep 15, 2026, and filed the results via an SEC Form 8‑K two days later.

Company-level read

Ticker impact

$ORMPNeutralHigh confidence
Context

SEC Form 8‑K discloses the results of ORMP's 2026 Annual Meeting, including director re‑elections and shareholder approvals of say‑on‑pay and stock‑plan amendments.

Expected impact

minimal; price likely unchanged

Evidence & confidence

The filing reports standard voting results; no material change to capital structure or strategy.

Market effects

Sector

none; governance update does not affect the broader pharmaceutical sector.

Regional

none; filing pertains only to ORMP shareholders.

Global

none

Counterpoint

What could challenge this read

Investors could view the expanded stock‑incentive plan as a slight dilution risk, but the impact is negligible.

Key entities

  • company
    ORAMED PHARMACEUTICALS INC.

    Subject of the filing; a pharmaceutical company listed on US exchanges.

Read at source← All news

Related articles

AUG 28
$NEOHighAI 8/10

Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

rttnews.com4 min
SEP 28
$AAPLLow

Apple Giving $25 to Owners of These iPhone Models

Apple will pay $25 per eligible iPhone to U.S. customers as part of a $250M settlement over delayed Siri AI launch. Claims can be submitted until December 21, with payments ranging from $25 to $95 per device. Eligible iPhones include models from iPhone 15 Pro to iPhone 16 Pro Max, purchased between June 2024 and March 2025. Apple denies allegations but settled to avoid trial costs.

macrumors.com2 min
SEP 28
$NVDAHighAI 9/10

Nvidia Unveils Record $150B Buyback as Stock Surges

Nvidia announced a $150B share buyback program, the largest in corporate history, signaling confidence in its AI business. The company's shares surged in after-hours trading. Nvidia's data center revenue grew from $3B in fiscal 2021 to $47B in fiscal 2024, driving the buyback. Analysts see this as a vote of confidence in sustained AI demand.

techbuzz.ai2 min
SEP 28
$NVDAHighAI 8/10

Jensen Huang Just Gave Investors 150 Billion Reasons to Buy Nvidia Stock

Nvidia (NVDA) announced a $150 billion share repurchase program, citing strong cash generation from AI-driven demand. CEO Jensen Huang attributed the move to confidence in long-term growth. The company has already repurchased $39 billion of stock in fiscal 2027 and plans to complete the new authorization by fiscal 2028.

fool.com2 min